I. COMPLETED MERGERS AND ACQUISITIONS

Company Acquired
(Country; Symbol)

Acquired By Or Merged With (Country; Symbol)

Date Announced

Date Completed

Value (M)***

Terms/Details


Arcaris Inc.*

Deltagen Inc.
(DGEN)

7/26

8/15

$12.5

Deltagen acquired Arcaris for 765,000 new shares, $450,000 in cash, plus transaction fees and expenses, as well as another 50,000 shares for Arcaris employee options; an additional 550,000 shares will be issued upon the achievement of certain milestones

Biotechna
U.A.B.
(Lithuania)*

Sicor Inc.
(SCRI)

7/25

7/25

$38.55

Sicor purchased Biotechna by issuing 1.5M shares and a warrant to purchase up to 150,000 shares of common stock at $3.50 per share; Sicor will assume about $30M in debt

Calydon
Inc.*

Cell Genesys
Inc.
(CEGE)

8/2

9/5

$17.4

Cell Genesys acquired Calydon for $17.4M in stock; it also took on $2.6M in Calydon debt

Cerebrotec*

ViaCell Inc.*

7/25

7/25

ND

ViaCell acquired Cerebrotec for equity of an undisclosed amount

DanProcess
A/S
(subsidiary
of Pantax;
Denmark)*

Amersham
Pharmacia
Biotech
(unit
of Nycomed
Amersham plc;
NYSE:NYE)

7/23

7/23

ND

Amersham said it acquired 100% of DanProcess for an undisclosed amount

Genetic
Models Inc.*

Charles River
Laboratories
Inc.
(NYSE:CRL)

7/5

7/20

$4

Charles River acquired Genetic Models for $4M in cash

Intermed
2000 Inc.
(Israel)*

Endovasc Ltd.
Inc.
(OTC
BB:ENDV)

7/10

9/4

ND

Endovasc acquired Intermed with an undisclosed amount of Endovasc common stock; Intermed will be a wholly owned subsidiary of Intermed

Isolagen
Technologies
Inc.*

American
Financial
Holding Inc.
(OTC BB:
ANFC)

8/22

8/22

$2

American Financial acquired Isolagen in a stock-for-stock transaction, and raised more than $2M in an equity private placement of common stock, and converted $1.45M principal amount of Isolagen debt and approximately $625,000 of accrued liabilities to equity

MultiCell
Associates
Inc.*

Exten
Industries
Inc.
(OTC BB:EXTI)

4/2

8/3

ND

Exten acquired MultiCell with an undisclosed amount of cash and stock

Novazyme
Pharma-
ceuticals
Inc.*

Genzyme
Corp.
(GENZ)

8/7

9/27

$137.5

Genzyme acquired Novazyme, paying $137.5M in stock, with Novazyme stockholders being eligible to receive two additional stock payments totaling $87.5M

Ophidian
Pharmaceu-
ticals Inc.
(OTC BB:
OPHD)

Hemoxymed
Inc.*

4/17

8/22

$9.5

Ophidian merged with Hemoxymed by acquiring all of Hemoxymed's stock in exchange for 19M new, unregistered Ophidian shares, about 94% of the company

Proligo
LLC*

Degussa Corp.
(subsidiary of
Degussa AG;
Germany)*

8/29**

8/31

US$14.3

Degussa paid US$14.3M to Gilead Sciences Inc. for the purchase of Gilead's 49% ownership, gaining 100% ownership; Degussa also provided $18M to Proligo for expansion purposes

Richcor
Resources
Ltd.
(Canada)*

BioxelPharma
Inc.
(Canada)*

7/31

7/31

ND

BioxelPharma acquired Richcor, exchanging 1,322 common shares of Richcor for each common share of Bioxel; Richcor shareholders now hold about 9% of Bioxel, or 2.64 million shares

Rosetta
Inpharmatics
Inc.
(RSTA)

Merck & Co.
Inc.

5/11

7/19

$540

Merck acquired Rosetta for about $540M net in stock; each share of Rosetta stock was converted into 0.2352 shares of Merck stock; Lazard Freres & Co. LLC served as adviser in the acquisition

Sequenom
Inc.
(SQNM)

Gemini
Genomics
plc
(UK; GMNI)

5/29

9/20

$238

Sequenom issued 12.9M shares to Gemini shareholders at an exchange rate of 0.2 Sequenom shares for each Gemini share, or 0.4 shares for each Gemini American depository shares

Thiemann SA
(Germany)*

Celltech Group
plc
(UK; NYSE:
CLL)

9/11

9/11

$45

Celltech purchased Thiemann for $45M in cash

V.I. Technologies
Inc.
's plasma
operations
(VITX)

Ampersand
Ventures*
and
other investors

8/14

8/14

$32

V.I. Technologies completed the divestiture of its plasma operations for $32M; the new privately held company will be called Precision Pharma Services Inc.

II. PENDING MERGERS AND ACQUISITIONS

Company To Be Acquired
(Country; Symbol)

Acquiring Company (Country; Symbol)

Date Announced

Expected Completion

Value (M)***

Terms/Details


Ambri Systems (Australia)*

Optecom Ltd. (Australia)*

7/25**

ND

A$10 (US$5.1)

Optecom said it will buy Ambri for A$10M

Axys Pharma-
ceuticals
Inc.
(AXPH)

Celera
Genomics
Group
(NYSE:CRA)

6/13

ND

$173

Celera plans to acquire Axys, issuing shares equivalent to $4.65 per share; the value of the deal is based on Axys' 37.3M shares outstanding

BioNative
AB

(Sweden)*

Viragen Inc.
(AMEX:VRA)
and Viragen
(Europe) Ltd.
(OTC BB:VERP)

7/12

ND

ND

Viragen and Viragen Europe signed a letter of intent to acquire BioNative for an undisclosed amount

Biosepra
(unit of Invitrogen
Corp.;
IVGN)

Ciphergen
Biosystems
Inc.
(CIPH)

6/26

ND

$12

Invitrogen plans to sell its BioSepra chromatography business for $12M in cash

Biosonix
Ltd.
(Israel)*

Neoprobe
Corp.
(OTC
BB:NEOP)

9/7

ND

$5.2

Neoprobe entered into a memorandum of understanding to acquire all of the outstanding shares of Biosonix, issuing about 11.8M shares, valuing the deal at about $5.2M

British
Biotech
plc's
discovery arm
(UK; BBIOY)

OSI Pharma-
cueticals
Inc.
(OSIP)

8/7

ND

#8.7
(US
$12.4)

British Biotech is selling its facilities in Oxford, and laboratory equipment, to OSI for US$12.4M

Cartesian
Technologies
Inc.*

Genomic
Solutions
Inc.
(GNSL)

9/7

4Q:01

$16

Genomic Solutions plans to acquire Cartesian by issuing 6.8M shares and spending $2.5M in cash

Corporate
Technology
Development
Inc.*

Endorex
Corp.*

8/1

ND

$10.6

Endorex plans to acquire all the outstanding capital stock of CTD in a stock-for-stock merger; Endorex will issue about 9.4M shares

Cytomatrix
LLC*

Select Thera-
peutics Inc.
(AMEX:XZL)

8/30

1Q:02E

ND

Select can acquire Cytomatrix in a tax-free exchange of shares from Feb. 1, 2002, to July 31, 2002

Eos Bio-
technology
Inc.*

Pharmacopeia
Inc.
(PCOP)

8/22

4Q:01

$197

Pharmacopeia will issue 10M new shares to buy Eos and assume options for an additional 600,000 shares; Pharmacopeia also will absorb Eos' $44M cash position

SBL Vaccin
AB
(subsidiary
of Active
Biotech AB;
Sweden;
SSE:ACTI)

PowderJect
Pharmaceu-
ticals plc
(UK;
LSE:PJP)

7/3

ND

$50

PowderJect plans to acquire SBL Vaccin for $50M in stock and cash

The Althexis
Company
Inc.*

Microcide
Pharmaceu-
ticals
Inc.
(MCDE)

7/30

4Q:01

$22

Microcide will acquire The Althexis Company by issuing about 5.3M shares for all outstanding shares of Althexis; the deal is valued at $22.22M

Viral
Genetics

Inc.*

5 Starliving
Online Inc.
(OTC BB:
HTHV)

9/19

9/01E

ND

5 Starliving will acquire Viral Genetics for about 30M shares; Viral will become a wholly owned subsidiary of 5 Starliving, and former stockholders will own about 79% of 5 Starliving's outstanding common stock


Notes:

# This chart is intended to include not only mergers and acquisitions of entire businesses, but also of divisions or subsidiaries of those businesses, where appropriate. It does not include acquisitions of single products or of manufacturing facilities and plants.

For those deals that are pending, and for which the acquiring company is issuing stock, the value of the transaction has been calculated based on the closing price on the day prior to the first announcement. For those deals that have been completed, and for which the acquiring company is issuing stock, the final value has been calculated based on the closing price on the date that the merger's completion was announced.

E = Estimated date, dependent on approval of regulatory authorities and shareholders of one or all companies involved in the transaction; ND = Not disclosed, reported and/or available; unless otherwise indicated, shares are traded on Nasdaq; AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SSE = Stockholm Stock Exchange.

* Private companies are indicated with an asterisk.

** Denotes the date the item ran in BioWorld International.

*** Conversions of non-U.S. currencies are calculated using the rate on the date the transaction closed, or for pending deals, on the date it was announced.

No Comments